Skip to main content
OpenTrials
Completed

NCT Number: NCT05217095

Clinical Trial on a Novel Blood Pumping System in 4008A Hemodialysis Machine

The aim of this clinical trial will be to verify the feasibility of using an impeller system instead of a roller pump for hemodialysis, using the established 4008 hemodialysis system and a Convergence Dialyzer with design changes made to the FX-Coral P 600 dialyzer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Special Hospital for Nephrology and Dialysis Diamed

Skopje, 1000, North Macedonia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must be up to 18-85 years
  • Hemodialysis Schedule: 3 times per week; app. 3- 5 hour treatment
  • Stable clinical conditions: no recent (last 2 weeks) hospitalization events, no recent main surgery (last 3 weeks), no acute cardiological problems, hemoglobine levels in the DOQI Guideline ranges.
  • Hemodynamic stability during dialysis i.c. number of sessions complicated by acute hypotension events or arrhythmia <25% in the last 3 Months
  • Well-functioning AVF vascular access: access recirculation ≤10%
  • No coagulation disorders and anticoagulant therapy
  • Patients must be using a similar size dialyzer as Convergence dialyzer
  • Signed Inform consent form.

Exclusion criteria

  • Unstable clinical condition: recent hospitalization, recent surgery, anemia, active neoplastic diseases,shock or unstable cardiac function and intolerable to extracorporeal treatment
  • Hemodynamic instability during the dialysis sessions; more than 25% of the sessions complicated by acute hypotension or arrhythmic events.Presence of clinically significant abnormality on a 12-lead ECG at Screening that, at the investigator's clinical judgment, may compromise the safety of the patient or affect the outcome of the study.
  • History or presence of congestive heart failure with symptoms consistent with New York Heart Association Class III or IV functional status within 6 months prior to the study Convergence system treatment.
  • Abnormal liver function values including but not limited to the aspartate transaminase, alanine transaminase or alkaline phosphatase ≥5 × upper limit normal.
  • Any uncontrolled clinically significant respiratory disease in the investigator's opinion (e.g., chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, asthma).
  • Temporary excluded will be patients with increased body temperature due to some infective disease, dehydration, diarrhea, hyperglycemia,
  • Severe bleeding, or history or evidence of bleeding diathesis or coagulopathy with the risk of bleeding or have to put on dialysis without anticoagulant.
  • Using temporary or permanent dialysis catheter
  • Uncontrolled diabetes mellitus or hypertension, at the discretion of investigator.
  • Known pregnancy and lactating without pregnancy test
  • Patient has known allergy or hypersensitivity reaction to dialyzer membrane or other disposable
  • Any conditions significantly affecting the nervous system (i.e., neuropathic conditions or nervous system damage
  • Patient shows evidence of a condition (psychological, emotional problems, any disorders or resultant therapy) that is likely to invalidate health information, consent, or limit the ability of the patient to comply with the protocol requirements in the opinion of the investigator
  • Any other conditions at the discretion of investigator not suitable for patients to participate in the study

Treatment and study plan

Convergence Dialyzer

Device

The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.

Primary outcomes

  1. Incidence of Alarms

    Time frame: 1 study day

    Incidence of alarms leading to end of treatment, cause identification

  2. Product defects

    Time frame: 1 study day

    Product defects leading to end of treatment, cause identification

  3. Serious adverse event / adverse event/ Serious adverse device effect/ Adverse device effect/Unanticipated serious adverse device effect

    Time frame: 1 study day

    Incidence of Serious adverse event / adverse event/ Serious adverse device effect/ Adverse device effect/Unanticipated serious adverse device effect

  4. Incidence of "recoverable" alarms

    Time frame: 1 study day

    Incidence of "recoverable" alarms, cause of alarms i.e.arterial/venous pressure outside of set range/limits

Secondary outcomes

  1. Completion Rate

    Time frame: 1 study day

    The completion rate of a dialysis session according to prescription. The study is considered to be successful, if at least 8 patients reach the effective dialysis time.

  2. Average Blood Flow Rate

    Time frame: 1 study day

    The average blood flow rate is measured during the dialysis treatment. Maintenance of preset blood flow rates throughout the dialysis in at least 8 out of 10 patients

  3. Arterial pressure

    Time frame: 1 study day

    The arterial pressure is measured in mmHg.

  4. Venous pressure

    Time frame: 1 study day

    The venous pressure is measured in mmHg.

  5. Impeller RPM

    Time frame: 1 study day

    The rotation of the impeller pump is measured in rpm.

  6. Dialysis Dose as single pool Kt/V

    Time frame: 1 study day

    The delivered dialysis dose as single-pool Kt/V. Achievement of a spKt/V > 1.4 in at least 8 out of 10 patients.

  7. Dialysis Dose as Urea Reduction Ratio (URR)

    Time frame: 1 study day

    The delivered dialysis dose as URR.

  8. Ultrafiltration Volume

    Time frame: 1 study day

    Total ultrafiltration volume (ml). Achievement of preset total ultrafiltration volume (ml) to reach dry weight target in at least 8 out of 10 patients.

  9. Body weight change

    Time frame: 1 study day

    Patient body weight change (before treatment vs. after treatment).

  10. pH

    Time frame: 1 study day

    The blood level of pH is measured pre/post HD. Achievement of results in laboratory acceptable ranges,

  11. Bicarbonate

    Time frame: 1 study day

    The blood level of Bicarbonate is measured pre/post HD. Achievement of results in laboratory acceptable ranges.

  12. Potassium

    Time frame: 1 study day

    The blood level of Potassium is measured pre/post HD. Achievement of results in laboratory acceptable ranges,

  13. Sodium

    Time frame: 1 study day

    The blood level of Sodium is measured pre/post HD. Achievement of results in laboratory acceptable ranges.

  14. Chloride

    Time frame: 1 study day

    The blood level of Chloride is measured pre/post HD. Achievement of results in laboratory acceptable ranges.

  15. Free hemoglobin

    Time frame: 1 study day

    The blood level of free hemoglobin (fHb measured on 30 min) to be in acceptable ranges for hemolysis

  16. Anticoagulation

    Time frame: 1 study day

    The total dose of anticoagulation consumption not to exceed patient treatment dose as I.U per kg

  17. Clotting Score

    Time frame: 1 study day

    The clotting score of dialyzer(visual check, using common scale for dialyzer study)

    • No visible thrombosed fibers
    • A few visible thrombosed fibers
    • Moderately visible thrombosed fibers
    • Many visible thrombosed fibers
    • Completely visible thrombosed fibers

    So the score goes from 1 (good) to 5 (bad).

Sponsors and collaborators

Lead sponsor

D.med Consulting GmbH

Industry

Collaborators

  • Fresenius Medical Care Deutschland GmbH

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 1, 2022
Registry last updated
Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.